These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32417104)

  • 1. The return of triglycerides and revival of omega-3 fatty acids!
    Ferrières J
    Arch Cardiovasc Dis; 2020; 113(6-7):369-373. PubMed ID: 32417104
    [No Abstract]   [Full Text] [Related]  

  • 2. [Update: clinical lipidology].
    Parhofer KG
    MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract]   [Full Text] [Related]  

  • 3. Pleiotropic effects of omega-3 fatty acids.
    Papazafiropoulou AK; Kardara MS; Pappas SI
    Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):40-6. PubMed ID: 22280222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
    Reddy KJ; Chowdhury S
    Future Cardiol; 2016 May; 12(3):261-8. PubMed ID: 27070379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention.
    Arca M; Borghi C; Pontremoli R; De Ferrari GM; Colivicchi F; Desideri G; Temporelli PL
    Nutr Metab Cardiovasc Dis; 2018 Mar; 28(3):197-205. PubMed ID: 29397253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
    Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
    Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
    Backes J; Anzalone D; Hilleman D; Catini J
    Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triglycerides and risk of atherosclerotic cardiovascular disease: An update.
    Farnier M; Zeller M; Masson D; Cottin Y
    Arch Cardiovasc Dis; 2021 Feb; 114(2):132-139. PubMed ID: 33546998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertriglyceridemia: A review of the evidence.
    Elkins C; Friedrich D
    Nurse Pract; 2018 Oct; 43(10):22-29. PubMed ID: 30153192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes.
    Bittner VA; Jacobson TA; Ballantyne CM; Guyton JR
    J Clin Lipidol; 2020; 14(1):4-15. PubMed ID: 32192643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy.
    Patel JV; Tracey I; Hughes EA; Lip GY
    Vasc Health Risk Manag; 2009; 5():801-10. PubMed ID: 19812692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.
    Kar S
    Am J Ther; 2014; 21(1):56-66. PubMed ID: 21975796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
    Weintraub HS
    Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
    Mason RP; Libby P; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.
    Sharp RP; Gales BJ; Sirajuddin R
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):83-92. PubMed ID: 29080985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis.
    Borow KM; Nelson JR; Mason RP
    Atherosclerosis; 2015 Sep; 242(1):357-66. PubMed ID: 26253795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.